23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
University of Sherbrooke
Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.
University of Sherbrooke
Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions.
University of Sherbrooke
C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action.
University of Sherbrooke
Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2.
University of Sherbrooke
Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin.
University of Sherbrooke
Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.
University of Sherbrooke
The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.
University of Sherbrooke
Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate.
University of Sherbrooke
Novel inhibitors of nucleoside triphosphate diphosphohydrolases: chemical synthesis and biochemical and pharmacological characterizations.
University of Sherbrooke
Preparation and biological activities of potential vasopressin photoaffinity labels.
University of Sherbrooke
[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.
University of Sherbrooke
Constraining the Side Chain of C-Terminal Amino Acids in Apelin-13 Greatly Increases Affinity, Modulates Signaling, and Improves the Pharmacokinetic Profile.
University of Sherbrooke
Structure-Activity Relationship and Bioactivity of Short Analogues of ELABELA as Agonists of the Apelin Receptor.
University of Sherbrooke
Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic.
University of Sherbrooke
Systematic replacement of amides by 1,4-disubstituted[1,2,3]triazoles in Leu-enkephalin and the impact on the delta opioid receptor activity.
University of Sherbrooke
In Search of the Optimal Macrocyclization Site for Neurotensin.
University of Sherbrooke
Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.
University of Sherbrooke
Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13).
University of Sherbrooke